Motherisk rounds: The Fetal Safety of Statins: A Systematic Review Meta-Analysis

Journal of Obstetrics and Gynaecology Canada

Volumn 36, Issue 6, 2014, Pages 506-509

  Zarek, Judith ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cholesterol; Congenital malformations; Pregnancy; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CHOLESTEROL;

ARTICLE; CONGENITAL MALFORMATION; DRUG INDICATION; DRUG USE; FETUS RISK; HUMAN; META ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TERATOGENESIS; CONGENITAL MALFORMATIONS; DRUG EFFECT; FEMALE; FETUS; PREGNANCY; REVIEW;

CHOLESTEROL; CONGENITAL MALFORMATIONS; PREGNANCY; STATINS;

FEMALE; FETUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREGNANCY;

EID: 84908070136     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30565-X     Document Type: Article

References (30)

1. Zarek J., Delano K.E., Nickel C., Laskin C., Koren K. Are statins teratogenic in humans? Addressing the safety of statins in light of potential benefits during pregnancy. Exp Rev Obstet Gynecol 2013, 8(6):513.
2. Koren G., Pastuszak A., Ito S. Drugs in pregnancy. N Engl J Med 1998, 338(16):1128-1137.
3. Sokalska A., Wong D.H., Cress A., Piotrowski P.C., Rzepczynska I., Villanueva J., et al. Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab 2010, 95:3453-3459.
4. Sokalska A., Cress A., Bruner-Tran K.L., Osteen K.G., Taylor H.S., Ortega I., et al. Simvastatin decreases invasiveness of human endometrial stromal cells. Biol Reprod 2012, 12:1-6.
5. Bruner-Tran K.L., Osteen K.G., Duleba A.J. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metabol 2009, 94:2489-2494.
6. Oktem M., Esinler I., Eroglu D., Haberal N., Bayraktar N., Zeyneloglu H.B. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 2007, 22(5):1474-1480.
7. Banaszewska B., Pawelczyk L., Spaczynski R.Z., Duleba A.J. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011, 96:3493-3501.
8. Rashidi B., Abediasl J., Tehraninejad E., Rahmanpour H., Sills E.S. Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial. J Investig Med 2011, 59:912-916.
9. Sathyapalan T., Smith K.A., Coady A.M., Kilpatrick E.S., Atkin S.L. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem 2012, 49(Pt 1):80-85.
10. Rashidi B., Abediasl J., Tehraninejad E., Rahmanpour H., Sills E.S. Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial. J Investig Med 2011, 59:912-916.
11. Raja-Khan N., Kunselman A.R., Hogeman C.S., Stetter C.M., Demers L.M., Legro R.S. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2011, 95:1849-1852.
12. Redecha P., van Rooijen N., Torry D., Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009, 113:4101-4109.
13. Kumasawa K., Ikawa M., Kidoya H., Hasuwa H., Saito-Fujita T., Morioka Y., et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci 2011, 108:1451-1455.
14. Singh J., Ahmed A., Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011, 58:716-724.
15. Minsker D.H., MacDonald J.S., Robertson R.T., Bokelman D.L. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 1983, 28:449-456.
16. Lankas G.R., Cukierski M.A., Wise L.D. The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res B Dev Reprod Toxicol 2004, 71:111-123.
17. Wise L.D., Cukierski M.A., Lankas G.R., Skiles G.L. The predominant role of maternal toxicity in lovastatin-induced developmental toxicity. Teratology 2000, 61:444.
18. Lescol, Product Information 2012, Novartis Pharmaceuticals Corp, East Hanover, NJ.
19. Zocor, Product Information 2012, Merck & Co. Inc., Whitehouse Station, NJ.
20. Edison R.J., Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004, 131:287-298.
21. Gibb H., Scialli A.R. Statin drugs and congenital anomalies. Am J Med Genet A 2005, 135:230-231.
22. Bar-Oz B., Moretti M.E., Mareels G., Van Tittelboom T., Koren G. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999, 354:1700-1701.
23. Ofori B., Rey E., Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007, 64:496-509.
24. Taguchi N., Rubin E.T., Hosokawa A., Choi J., Ying A.Y., Moretti M.E., et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008, 26:175-177.
25. McGrogan A., Snowball J., de Vries C.S. Statins and pregnancy outcomes: a cohort study in the GPRD. Pharmacoepidemiol Drug Saf 2009, 18(Suppl):S75-S76.
26. Colvin L., Slack-Smith L., Stanley F.J., Bower C. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010, 19:1137-1150.
27. Paulus W.E., Schloemp S., Stoz F. Statin treatment in hypercholesterolemic mothers during early pregnancy. Geburtshilfe Frauenheilkd 2008, 68:S130.
28. Winterfeld U., Allignol A., Panchaud A., Rothuizen L.E., Merlob P., Cuppers-Maarschalkerweerd B., et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013, 120:463-471.
29. ISRCTN Register. Statins to ameliorate early onset pre-eclampsia. Available at: . Accessed March 12, 2014. http://www.controlled-trials.com/ISRCTN23410175.
30. Clinical Trials.gov. Pravastatin for prevention of preeclampsia. Available at: . Accessed March 12, 2014. http://clinicaltrials.gov/ct2/show/NCT01717586.